SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a top trending stock as the market eagerly anticipates its highly contested earnings report, driving sharply divided community sentiment. Its recent all-cash bid for Warner Bros. Discovery assets is a major talking point, adding a complex layer to discussions around its growth trajectory. Amidst broader market volatility, many are actively debating if Netflix's streaming business makes it a 'tariff-proof' play.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst significant market volatility, fueled by discussions surrounding former President Trump's public statements on geopolitical issues, including Greenland and proposed tariffs, which are sparking international concern and market reactions. Community chatter is highly polarized, with supporters pointing to a new digital token initiative as a potential short squeeze catalyst, while critics link the former President's rhetoric to broader market instability and question the stock's underlying value.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending sharply lower amid market apprehension stirred by Trump's recent rhetoric regarding potential tariffs on NATO allies and ambitions for Greenland. The community is intensely divided, with many attributing the significant sell-off to his statements and broader geopolitical concerns, while others are closely watching for technical support levels and potential short-term rebounds.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending amidst a persistent downtrend, causing frustration among some investors profiting from puts, while others aggressively "buy the dip" citing historically oversold conditions. This comes ahead of its anticipated strong December-quarter earnings, with bulls expecting robust iPhone demand and new AI partnerships with Google Gemini, despite ongoing concerns about memory chip costs and broader geopolitical trade tensions.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently trending due to impressive positive data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis, showcasing significant efficacy and a favorable safety profile. This has ignited strong bullish sentiment and a substantial surge in its share price, as the community discusses the drug's potential as a game-changer in a large and growing market. Amid the excitement, investors are actively debating the prospect of future capital raises to fund ongoing development, contrasting with confidence in the company's long-term value and potential for partnerships.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to optimistic developments following an FDA meeting for its ANKTIVA therapy, where no new clinical trials were requested for its bladder cancer application, significantly de-risking its path to resubmission. This news, coupled with exceptionally high trading volume and resilience in a down market, has fueled a strong bullish sentiment among the community, which anticipates a significant short squeeze and long-term potential for its broad cancer treatment pipeline.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending amid heightened global trade tensions driven by discussions surrounding new tariffs and geopolitical events, notably the Greenland situation, compounded by concerns over a global bond market sell-off. Community sentiment is sharply divided, with many anticipating further weakness for technology and growth stocks, while others view current price action as an overreaction and a 'buy the dip' opportunity, often tied to expectations of a market rebound or perceived market resilience.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. (CRML) is drawing significant attention amidst escalating geopolitical discussions surrounding Greenland's critical rare earth deposits, with community members closely tracking potential US involvement and the company's strategic role in Western supply chains. Investors are eagerly anticipating CRML's upcoming business update call, widely viewed as a potential catalyst for further project clarity and financing news. Despite recent price volatility, many perceive current dips as accumulation opportunities, fueled by strong conviction in the company's long-term potential in the burgeoning critical minerals sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently a major topic due to mounting geopolitical tariff threats and widespread anticipation of its upcoming earnings report, with many community members expressing concern over potentially "disastrous" results. Investors are actively debating the stock's valuation, questioning its Full Self-Driving advancements, and observing increasing competition within a saturating global EV market.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to reports of Zydus Lifesciences exploring a controlling stake or key asset acquisition, alongside strong preliminary revenue figures and a significant patent extension for IBSRELA and XPHOZAH until 2041. The community is buzzing about the game-changing patent extension, accelerating IBSRELA's path to $1 billion in annual revenue by 2029, and speculating on a potential buyout or bidding war, despite some historical skepticism around sustained gains. Analysts have responded with multiple price target upgrades, highlighting the company's strengthened long-term valuation and potential for sustained growth with two approved drugs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$LTRN BRIEF-Lantern Pharma Reports Additional Positive Lp-184 Phase 1A Results Showing Durable Disease Control In Heavily Pre-Treated Advanced Cancer Patients 
REUTERS 7:41 AM ET 12/3/2025

StockTwits Web

Lantern Pharma Inc

 BRIEF-Lantern Pharma Reports Additional Positive Lp-184 Phase 1A Results Showing Durable Disease Control In Heavily Pre-Treated Advanced Cancer Patients 
REUTERS 7:41 AM ET 12/3/2025